Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker
Our findings suggest BEND3 is a potential prognostic and immune-related cancer biomarker. Its overexpression in multiple cancers, association with poor survival, and role in tumor immunity support its oncogenic function. Functional analysis indicates it may regulate key cancer pathways. Importantly, in vitro experiments confirm its tumor-promoting effects in breast cancer, providing a foundation for further study of BEND3's mechanisms and therapeutic implications.
Authors
- Chenming Guo (ORCID: https://orcid.org/0000-0002-4531-8958)
- Dilimulati Ismtula
- Yiyang Wang (ORCID: https://orcid.org/0000-0001-6207-4716)
- Haotian Ma
- Yongxiang Li
- Haocong Li
- Yuting Gou
- Reyima Geni
Institutions
- Xinjiang Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/bctt.s553681
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00